Evidence map›Paper›PMID 35854202›Full record

ReviewThe AAPS journal2022

Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.

Carl Petersson, Xin Zhou, Joerg Berghausen, David Cebrian, Michael Davies, Kevin DeMent, Peter Eddershaw, Arian Emami Riedmaier, Alix F Leblanc, Nenad Manveski and 11 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Species Dependent Metabolism of a Covalent nsP2 Protease Inhibitor withbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Carl PeterssonThe Healthcare Business of Merck KGaA, Frankfurter Str. 250, Postcode D50/902, 64293, Darmstadt, Germany. carl.petersson@merckgroup.com.
Xin ZhouEli Lilly and Company, Indianapolis, IN, USA.
Joerg BerghausenNovartis, Basel, Switzerland.
David CebrianGSK, Brentford, UK.
Michael DaviesAstraZeneca, Cambridge, UK.
Kevin DeMentTakeda Pharmaceuticals International, Inc., Deerfield, IL, USA.
Peter EddershawVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Arian Emami RiedmaierBristol-Myers Squibb, New York, NY, USA.
Alix F LeblancAbbVie Inc., North Chicago, IL, USA.
Nenad ManveskiF. Hoffman-La Roche Ltd., Basel, Switzerland.
Punit MaratheAgios Pharmaceuticals, Cambridge, MA, USA.
Panteleimon D MavroudisSanofi, Paris, France.
Robin McDougallAlnylam Pharmaceuticals, Inc., Cambridge, MA, USA.
Neil ParrottF. Hoffman-La Roche Ltd., Basel, Switzerland.
Andreas ReichelBayer AG, Leverkusen, Germany.
Charles RotterTakeda Pharmaceuticals International, Inc., Deerfield, IL, USA.
David TessPfizer, Inc., New York, NY, USA.
Laurie P VolakJanssen Research and Development, LLC, Raritan, NJ, USA.
Guangqing XiaoSunovion Pharmaceuticals, Inc., Marlborough, MA, USA.
Zheng YangBristol-Myers Squibb, New York, NY, USA.
James BakerMerck and Co., Inc, Kenilworth, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of human clearance (CL) and volume of distribution at steady state (V

Indexed as

Drug IndustryModels, BiologicalHumansKineticsPharmaceutical PreparationsPharmaceutical PreparationsClearanceHuman PK predictionIQ ConsortiumUncertaintyVolume of distribution

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.